Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Assetmark Inc.

Assetmark Inc. grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.3% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,177,364 shares of the biopharmaceutical company’s stock after acquiring an additional 109,118 shares during the quarter. Assetmark Inc.’s holdings in Gilead Sciences were worth $182,550,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. nVerses Capital LLC purchased a new position in Gilead Sciences during the third quarter worth about $25,000. Valued Wealth Advisors LLC increased its holdings in shares of Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 161 shares during the last quarter. CarsonAllaria Wealth Management Ltd. raised its position in shares of Gilead Sciences by 198.3% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 238 shares during the period. Strategic Investment Solutions Inc. IL acquired a new position in Gilead Sciences in the second quarter valued at approximately $33,000. Finally, Cedar Wealth Management LLC grew its position in Gilead Sciences by 51.6% in the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 160 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Down 1.4 %

Shares of NASDAQ:GILD opened at $96.57 on Friday. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.32. The stock has a market cap of $120.22 billion, a price-to-earnings ratio of 1,072.94, a price-to-earnings-growth ratio of 3.19 and a beta of 0.17. The firm’s 50 day moving average price is $85.30 and its 200 day moving average price is $75.03.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. The business had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 28.60%. The company’s revenue was up 7.0% on a year-over-year basis. During the same period last year, the business earned $2.29 EPS. As a group, equities research analysts predict that Gilead Sciences, Inc. will post 3.76 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be given a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, December 13th. This represents a $3.08 annualized dividend and a dividend yield of 3.19%. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.

Analysts Set New Price Targets

Several equities analysts have recently commented on GILD shares. Piper Sandler upped their price target on Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday. JPMorgan Chase & Co. upped their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday. Wells Fargo & Company lifted their price target on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday. Evercore ISI upgraded shares of Gilead Sciences to a “strong-buy” rating in a report on Friday, August 9th. Finally, Sanford C. Bernstein began coverage on shares of Gilead Sciences in a report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 target price for the company. Twelve research analysts have rated the stock with a hold rating, ten have issued a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $90.71.

Insider Activity

In other news, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares in the company, valued at approximately $6,545,480.06. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Merdad Parsey sold 25,590 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the transaction, the insider now owns 99,599 shares in the company, valued at $9,113,308.50. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the transaction, the insider now directly owns 78,127 shares in the company, valued at approximately $6,545,480.06. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 62,437 shares of company stock worth $5,374,825. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.